Accelerate Diagnostics (AXDX) Stock Forecast, Price & News

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Accelerate Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Accelerate Diagnostics.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its quarterly earnings data on Monday, May, 16th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.09. During the same period last year, the business posted ($0.41) earnings per share.
View Accelerate Diagnostics' earnings history.

What price target have analysts set for AXDX?

2 analysts have issued 1 year price objectives for Accelerate Diagnostics' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Accelerate Diagnostics' share price to reach $1.00 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:

• Mr. Jack Phillips, CEO, Pres & Director (Age 56, Pay $703.01k) (LinkedIn Profile)
• Mr. Steve Reichling, Chief Financial Officer (Age 44, Pay $340k) (LinkedIn Profile)
• Mr. Ron Price, Chief Commercial Officer of Americas (Age 58, Pay $240k) (LinkedIn Profile)
• Laura Pierson, Investor Relations Officer
• Mr. Michael Bridge, Sr. VP, Gen. Counsel & Sec.
• Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
• Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
• Ms. Laura Costa, Sr. VP & Head of Global Customer Support
• Mr. John Meduri, Chief Strategy Officer
• Dr. Lawrence Mertz, Sr. VP and Head of R&D

Who are some of Accelerate Diagnostics' key competitors?

Some companies that are related to Accelerate Diagnostics include Standard BioTools (LAB), Harvard Bioscience (HBIO), Codex DNA (DNAY), IsoPlexis (ISO), Scientific Industries (SCND), Talis Biomedical (TLIS), Astrotech (ASTC), Precipio (PRPO), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), SeqLL (SQL), Arrayit (ARYC), DiaSys (DYXC), Orthometrix (OMRX) and PositiveID (PSID).
View all of AXDX's competitors.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.31%), Baird Financial Group Inc. (2.50%), Griffin Asset Management Inc. (2.16%), Vanguard Group Inc. (1.90%), State Street Corp (1.77%) and Cladis Investment Advisory LLC (0.81%). Company insiders that own Accelerate Diagnostics stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, BlackRock Inc., Group One Trading L.P., and Simplex Trading LLC. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., Baird Financial Group Inc., Cladis Investment Advisory LLC, State Street Corp, GSA Capital Partners LLP, JPMorgan Chase & Co., Goldman Sachs Group Inc., and Allworth Financial LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Hany Massarany, and Jack W Schuler.
View insider buying and selling activity for Accelerate Diagnostics or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $0.60.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $41.80 million and generates $11.78 million in revenue each year. The medical research company earns $-77.70 million in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 220 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100, via email at [email protected], or via fax at 520-269-6580.